Optimal delivery time for patients with diet-controlled gestational diabetes mellitus: a single-center real-world study

Zongzhi Yin1,2,3*, Tengteng Li2, Lu Zhou1, Jiajia Fei1, Jingjing Su1 and Dan Li4

Abstract

Background: To determine the optimal delivery time for women with diet-controlled gestational diabetes mellitus by comparing differences in adverse maternal–fetal outcome and cesarean section rates.

Methods: This real-world retrospective study included 1,050 patients with diet-controlled gestational diabetes mellitus who delivered at 35–42 weeks’ gestation. Data on patient characteristics, maternal–fetal outcomes, and cesarean section rate based on fetal gestational age were collected and analyzed. Differences between deliveries with and without iatrogenic intervention were also analyzed.

Results: The cesarean section rate at ≥ 41 weeks’ gestation was significantly higher than that at 39–39 + 6 weeks (56% vs. 39%, p = 0.031). There were no significant differences in multiple adverse maternal or neonatal outcomes at delivery before and after 39 weeks. Vaginal delivery rates were increased significantly at 39–39 + 6 weeks due to iatrogenic intervention (p = 0.005) and 40–40 + 6 weeks (p = 0.003) in patients without and with spontaneous uterine contractions, respectively.

Conclusions: It’s recommended that optimal delivery time for patients with diet-controlled gestational diabetes mellitus should be between 39- and 40 + 6 weeks’ gestation. Patients who have Bishop scores higher than 4 can undergo iatrogenic intervention at 39–39 + 6 weeks. However iatrogenic interventions are not recommended for patients with low Bishop scores.

Keywords: Gestational diabetes mellitus, Optimal delivery time, Maternal–fetal outcome, Iatrogenic intervention, Uterine contraction

Background

Gestational diabetes mellitus (GDM) is defined as the onset or first recognition of glucose intolerance during pregnancy [1]. This condition is one of the most common obstetric complications of pregnancy; with its prevalence varying substantially worldwide from 1.8% to more than 31.0%, which continues to increase [2, 3]. The blood glucose levels in women with GDM can usually be controlled through diet, exercise, or medication. Between 70–85% of women achieve euglycemia through diet or exercise and this is referred to as diet-controlled GDM. Patients who control hyperglycemia using medication are regarded as having medication-treated GDM. The number of patients with diet-controlled GDM is much higher than that of patients with medication-treated GDM [1, 2, 4].

Previous studies [1, 2, 5–7] have shown that the incidence of maternal and fetal complications significantly increases in cases involving GDM. Maternal and fetal complications include premature rupture of membrane (PROM) (22.6% vs. 11.5%), perineal laceration (18% vs.
10.7%), hypoglycemia (4.3% vs. 0.03%), shoulder dystocia/birth injury (4.3% vs. 2.6%), macrosomia (20.63% vs. 4.0%), and neonatal respiratory distress (14.55% vs. 3.0%), respectively. Furthermore, in several studies [8, 9], the incidence of complications was higher in patients with medication-treated GDM than in those with diet-controlled GDM (i.e., a 58% vs. 40% cesarean section rate).

Glycemic management is the main measure to reduce the occurrence of GDM complications in pregnant women. The optimal time and mode of delivery for patients with GDM is primarily based on glycemic control. Recommendations for women with medication-treated GDM are consistent across multiple clinical guidelines calling to proceed for the induction of labor at 39–39 + 6 weeks of gestation [2, 10]. However, various guidelines for diet-controlled GDM do not provide clear recommendations for optimal delivery time [11]. The 2018 American College of Obstetricians and Gynecologists (ACOG) guidelines recommend that delivery in women with diet-controlled GDM should not be induced before 39 weeks of gestation, which leaves a large span of time from 39 to 41 weeks for delivery. The guidelines of the 2020 Society of Obstetricians and Gynecologists of Canada (SOGC) suggest that induction by the 40-week mark may be beneficial for this population [2, 10]. Furthermore, the studies on which the guideline recommendations are based also have limitations. The 2018 ACOG guideline is based on the outcome of a multicenter open-label randomized controlled trial that was published in the British Journal of Obstetrics and Gynecology; it included only 425 patients with an overrepresentation of white individuals (73.6%), which may have produced false-negative results that might have been a limitation [12]. The 2020 SOGC guidelines are based on the results of a retrospective cohort study [13] which was published in the International Journal of Gynecology and Obstetrics. In this study, the differences in stillbirth rates between women with and without diet-controlled GDM were compared. No difference between groups was found before 40 weeks of gestation, but there was a significantly lower stillbirth rate after 40 weeks in those with diet-controlled GDM. However, that study illustrated that women with diet-controlled GDM were routinely induced at 40 weeks of gestation. It was not clearly stated whether there were differences in the clinical characteristics of women who delivered after 40 weeks of gestation. It was also not indicated whether iatrogenic intervention should be implemented before 41 weeks of gestation according to GDM status or if there was an optimal delivery time between 39 and 41 weeks of gestation. Hence, this study aimed to determine the optimal delivery time for women with diet-controlled diabetes mellitus by comparing differences in adverse maternal–fetal outcome and cesarean section rates.

Methods

Study Population

This retrospective cohort study included 1,050 singleton pregnancies with diet-controlled GDM. All patients were hospitalized in the Department of Obstetrics and Gynecology of The First Affiliated Hospital of Anhui Medical University between January 1, 2018, and December 31, 2020 and all included patients were of Asian origin. The study design was approved by the First Affiliated Hospital of Anhui Medical University Ethics Committee for the Protection of Human Subjects in Research (PJ2020-06-12). The need for acquisition of informed consent was waived owing to the retrospective nature of this study. All methods were carried out in accordance with relevant guidelines and regulations.

Diagnosis of patients with GDM was made according to the Chinese Society of Obstetrics and Gynecology and the Chinese Medical Association consensus [14]. One or more of the following values from a 75-g oral glucose tolerance test (OGTT) between the 24th and 28th week of gestation must be measured to meet the diagnostic criteria for GDM: fasting plasma glucose (FPG) ≥ 5.1 mmol/L (92 mg/dL), 1-h plasma glucose ≥ 10.0 mmol/L (180 mg/dL), and 2-h plasma glucose ≥ 8.5 mmol/L (153 mg/dL). Patients with GDM who followed standard management of their diet and exercise performed blood glucose control for 2 weeks after which their plasma glucose levels were assessed again. Patients who maintained a fasting glucose of ≤ 5.3 mmol/L and a 2-h postprandial glucose of ≤ 6.7 mmol/L were considered well-controlled and were included in our study as patients with diet-controlled GDM. These patients underwent standard diet management and weekly plasma glucose checks until delivery. The treatment was adjusted according to the conditions and needs of the woman.

Patients aged 18 years or older with a singleton pregnancy, vertex presentation, and who were diagnosed with GDM with well-controlled blood glucose in their current pregnancy were included. Patients with any of the following conditions were excluded from the study: gestational age at birth of less than 35 weeks’ gestation, pregestational diabetes mellitus, GDM patients requiring medication control, multiple pregnancies, placenta previa, scarred uterus, fetal malposition (transverse, breech), and medical/surgical comorbidity as an indication for cesarean section. All gestational ages were verified using the last menstrual period and confirmed using the first trimester sonographic measurement of crown-rump length.

All patients delivered at ≥ 35 weeks of gestation, and the patient groups were formed according to the
week of gestation at delivery. Patients who delivered at 35–36 + 6 weeks comprised the <37 gestational week group. The patient clinical information and adverse perinatal maternal and neonatal outcomes were collected at <37 W, 37–37 + 6 W, 38–38 + 6 W, 39–39 + 6 W, 40–40 + 6 W, and ≥ 41 weeks’ gestation.

**Outcome Measures**

We divided all outcomes into two categories: pregnancy complications and maternal outcomes, and fetal and neonatal outcomes. All diagnostic criteria followed the clinical guidelines published by the Chinese Society of Obstetrics and Gynecology and the Chinese Medical Association. All the diagnoses were made by a senior obstetrician to reduce the error and ensure data accuracy.

**Pregnancy Complications and Maternal Outcomes**

A preeclampsia diagnosis was made according to the “Diagnosis and management of hypertension in pregnancy (2020) [15],” which was defined by at least two outcomes: ≥4-h interval with systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and random positive urine protein of ≥ 0.3 g/24 h. We defined PROM according to the “Diagnosis and Management of Premature Rupture of Membranes (2015) [16],”—which defines a rupture of membranes before the onset of labor and vaginal fluid flow as premature rupture after 28 weeks of gestation. The definition of postpartum hemorrhage (PPH) was based on the “Prevention and Treatment of Postpartum Hemorrhage (2014) [17],” which states that a PPH is the blood loss of more than 500 mL within 24 h after delivery of the fetus in vaginal delivery and more than 1000 mL in cesarean delivery. An amniotic fluid volume of less than 300 mL, a maximum vertical depth of amniotic fluid ≤ 2 cm, and an amniotic fluid index (AFI) ≤ 5 cm in late pregnancy was considered as oligohydramnios. In cases of yellowish-green or brownish green amniotic fluid, with a large amount of meconium or pasty-like sticky meconium, III-polluted amniotic fluid was considered.

Perineal laceration was defined as any injury in the genital area that occurred from lacerations during labor, involving the skin of the perineum and vaginal mucosa to the deeper rectal mucosa. Poor healing of the perineum was defined as the manifestation of fever, painful incision, yellow purulent secretions, and positive bacterial culture within 3 days of delivery. Obstructed shoulder delivery was diagnosed when there was a failure to deliver the fetal shoulder(s) with a gentle downward traction on the fetal head, resulting in the requirement of additional obstetric maneuvers for delivery of the fetus. Postoperative pyrexia was defined as two recordings of an oral temperature higher than 38 °C daily (at 4-h intervals) measured within 10 days after delivery.

**Fetal and Neonatal Outcomes**

We defined asphyxia neonatorum according to the “Expert Consensus on the Diagnosis of Neonatal Asphyxia (2016) [18],” which is defined as a 1-min Apgar score ≤ 7- or 5-min Apgar score ≤ 7 with a cord arterial blood pH < 7.2. The definition of neonatal respiratory distress was in accordance with that in the “Diagnosis and Treatment of Neonatal Respiratory Distress (2013) [19],” which includes the following criteria: 1) acute onset in neonates; 2) clear perinatal triggers; 3) typical clinical signs (progressive dyspnea, cyanosis, and reduced or absent lung breath sounds); and 4) an arterial blood gas analysis of PaO₂/FiO₂ ≤ 200 mmHg. The diagnosis of fetal distress was made according to the following criteria: 1) abnormal fetal heart rate (fetal heart rate < 100 bpm), 2) baseline variability ≤ 5 bpm, 3) fetal movements < 10 times/12 h or absent fetal movements. A fetal birth weight ≥ 4000 g was considered fetal macrosomia. If the fetal serum glucose level was lower than 2.6 mmol/L within 24 to 72 h after delivery neonatal hypoglycemia was considered.

**Decision of Delivery**

The decision for timing and mode of delivery was determined based on two of the following scenarios: 1) for patients who were admitted to the hospital with regular uterine contraction and treated according to the normal course of labor; and 2) for those who had pregnancy complications, final decisions were made by a senior obstetrician based on the clinical guidelines for the management of the related diseases. The indication for iatrogenic intervention was based on the patient’s Bishop score and the gestational age. The Chinese GDM bulletin was followed. Iatrogenic interventions were given before 41 weeks of gestation for these patients without spontaneous uteri contractions and the Bishop scores were evaluated [14]. If the score exceeded 4, low-dose oxytocin or dinoprostone was used to induce labor. For patients with a low Bishop score, balloon was used for cervical dilation.

**Statistical Analysis**

SPSS version 19.0 was used for the statistical processing of the data. The measurement data are expressed as the mean ± standard deviation, and the counting data as numbers (percentages). Mean values were compared between multiple groups of measurement data. One-way analysis of variance was used to conform data to a normal distribution, and Student–Newman–Keuls tests were used for pairwise comparisons among groups. Data that were not normally distributed were analyzed using
Results

Patient Characteristics

Table 1 shows patient characteristics according to weeks of gestation at delivery. Maternal age in the 37–37+6 gestational weeks group was significantly higher than that in the 39–39+6 group ($p=0.005$), while maternal age in the 40–40+6 and ≥41 groups was significantly lower than that in the 39–39+6 group ($p=0.001$ and 0.036, respectively). Maternal body mass indices (BMIs) before pregnancy in the 37–37+6 and ≥41 groups were significantly higher than in the 39–39+6 group ($p=0.022$ and 0.002, respectively). The changes in BMI during pregnancy were not significantly different between groups.

Maternal Outcomes

Table 2 shows maternal delivery outcomes (by weeks of gestation at delivery) in patients with diet-controlled GDM. The results showed that the rate of macrosomia was not significantly different between the 39–39+6 gestational weeks group and other groups, except that no macrosomia was present at <37 weeks. Compared with the 39–39+6 gestational weeks group, the rate of III-polluted amniotic fluid rate at 37–37+6 weeks was significantly lower ($p=0.033$). The incidences of postnatal hypoglycemia and vomiting and moaning at <37 gestational weeks were significantly higher than those in the 39–39+6 gestational weeks group ($p=0.049$ and 0.028, respectively); these incidences were not significantly different from those in the other gestational week groups. There were no significant differences in the incidence of neonatal asphyxia, neonatal respiratory distress syndrome, or neonatal malformations.

Neonatal Outcomes

Table 3 shows neonatal outcomes (by weeks of gestation at delivery) in patients with diet-controlled GDM. The results showed that the rate of macrosomia was not significantly different between the 39–39+6 gestational weeks group and other groups, except that no macrosomia was present at <37 weeks. Compared with the 39–39+6 gestational weeks group, the rate of III-polluted amniotic fluid rate at 37–37+6 weeks was significantly lower ($p=0.033$). The incidences of postnatal hypoglycemia and vomiting and moaning at <37 gestational weeks were significantly higher than those in the 39–39+6 gestational weeks group ($p=0.049$ and 0.028, respectively); these incidences were not significantly different from those in the other gestational week groups. There were no significant differences in the incidence of neonatal asphyxia, neonatal respiratory distress syndrome, or neonatal malformations.

Indications for Cesarean Section

As shown in Table 4, compared with the 39–39+6 gestational weeks group, the rate of cesarean delivery due to macrosomia at <37 and 38–38+6 weeks was significantly lower ($p=0.040$ and 0.022, respectively). The indication due to oligohydramnios at 37–37+6, 38–38+6, and ≥41 weeks was significantly higher ($p=0.034$, 0.020, and 0.025, respectively), and the indication due

| Table 1 Patient Characteristics |
|---------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Gestational Week                | 39–39+6 W        | < 37 W           | < 37 W           | 37–37+6 W        | 38–38+6 W        | 40–40+6 W        | ≥ 41 W           |
| N                               | 372              | 40               | 40               | 74               | 220              | 294              | 50               |
| Age (Years)                     |                  |                  |                  |                  |                  |                  |                  |
| Median                          | 29.0             | 29.0             | 29.0             | 29.0             | 29.0             | 29.0             | 28.0             |
| (Min, Max)                      | (19.43, 43)      | (21, 35)         | (21, 35)         | (23.48, 41)      | (20.39, 41)      | (16.39, 41)      | (21.38, 41)      |
| P-value                         | 0.188            | 0.188            | 0.005            | 0.599            | 0.001            | 0.036            |
| BMI before Pregnant (kg/m²)      |                  |                  |                  |                  |                  |                  |                  |
| Mean ± SD                       | 22.01 ± 3.418    | 22.95 ± 3.782    | 22.95 ± 3.782    | 23.05 ± 3.674    | 22.34 ± 3.459    | 22.16 ± 3.164    | 23.73 ± 4.019    |
| Median                          | 21.60            | 22.40            | 22.40            | 23.05            | 21.90            | 21.80            | 23.85            |
| (Min, Max)                      | (15.1, 47.8)     | (14.1, 34.8)     | (14.1, 34.8)     | (16.0, 39.3)     | (14.0, 37.3)     | (12.5, 34.2)     | (17.4, 37.7)     |
| P-value                         | 0.122            | 0.122            | 0.022            | 0.026            | 0.586            | 0.002            |
| BMI change during Pregnant (kg/m²) |                  |                  |                  |                  |                  |                  |                  |
| Mean ± SD                       | 5.45 ± 1.719     | 5.06 ± 1.744     | 5.06 ± 1.744     | 5.02 ± 1.615     | 5.42 ± 1.853     | 5.60 ± 1.832     | 5.47 ± 1.533     |
| Median                          | 5.40             | 5.00             | 5.00             | 4.80             | 5.40             | 5.50             | 5.55             |
| (Min, Max)                      | (0.0, 11.6)      | (0.7, 9.4)       | (0.7, 9.4)       | (1.6, 8.4)       | (0.0, 12.5)      | (0.0, 12.0)      | (1.9, 8.7)       |
| P-value                         | 0.197            | 0.197            | 0.055            | 0.816            | 0.289            | 0.944            |
to preeclampsia at <37 weeks was significantly higher than that in the 39–39+6 gestational weeks group ($p = 0.015$).

Regarding comparison of the mode of delivery, the results showed that the rate at which natural labor switched to cesarean section delivery at 40–40+6 and ≥ 41 gestational weeks was higher than that at 39–39+6 weeks. However the differences were not statistically significant ($p = 0.059$ and 0.071, respectively).

The natural labor rate was calculated as the total number of vaginal deliveries / total number of births and the P values were calculated for the difference of

### Table 2 Maternal Outcomes

| Gestational Week | 39–39+6 W | <37 W | 37–37+6 W | 38–38+6 W | 40–40+6 W | ≥ 41 W |
|------------------|-----------|------|-----------|-----------|-----------|--------|
| PROM (N)         | 372       | 40   | 74        | 220       | 294       | 50     |
| Yes(n, %)        | 90 (24.2%)| 23 (57.5%) | 28 (37.8%)| 67 (30.5%)| 51 (17.3%)| 7 (14.0%)|
| No(n, %)         | 282 (75.8%)| 17 (42.5%) | 46 (62.2%)| 153 (69.5%)| 243 (82.7%)| 43 (86.0%)|
| Risk Diff (95% CI) | 33.31% (17.3%,49.2%) | 13.64% (1.77%,25.52%) | 6.26% (-1.22%,13.74%) | -6.85% (-12.98%,-0.71%) | -10.19% (-20.75%,0.36%) |
| P-value          | 0.000     | 0.020| 0.102     | 0.036     | 0.151     |
| Delivery Method (N) | 372       | 40   | 74        | 220       | 294       | 50     |
| C-section(n, %)  | 145 (39.0%)| 16 (40.0%) | 33 (44.6%)| 104 (47.3%)| 127 (43.2%)| 28 (56.0%)|
| Natural Delivery(n, %) | 227 (61.0%)| 41 (55.4%) | 116 (52.7%)| 167 (56.8%)| 22 (44.0%)|
| Risk Diff (95% CI) | 1.02% (-14.95%,16.9%) | 5.62% (-6.75%,17.98%) | 8.20% (0.04%,16.55%) | 4.22% (-3.31%,11.74%) | 17.02% (2.40%,31.65)
| P-value          | 1.000     | 0.367| 0.058     | 0.302     | 0.031     |
| GDM-related Complications (N) | 372       | 40   | 74        | 220       | 294       | 50     |
| Yes(n, %)        | 70 (18.8%)| 9 (22.5%) | 10 (13.5%)| 37 (16.8%)| 56 (19.0%)| 13 (26.0%)|
| No(n, %)         | 302 (81.2%)| 31 (77.5%) | 64 (86.5%)| 183 (83.2%)| 238 (81.0%)| 37 (74.0%)|
| Risk Diff (95% CI) | 3.68% (-9.85%,17.22%) | -5.30% (-14.05%,3.44%) | -2.00% (-8.34%,4.34%) | 0.23% (-5.76%,6.22%) | 7.18% (-5.61%,19.97)
| P-value          | 1.000     | 1.000| 1.000     | 1.000     | 1.000     |
| Perineal laceration (N) | 227       | 24   | 41        | 116       | 167       | 22     |
| Yes(n, %)        | 147 (64.8%)| 18 (75.0%) | 29 (70.7%)| 79 (68.1%)| 94 (56.3%)| 7 (31.8%)|
| No(n, %)         | 80 (35.2%)| 6 (25.0%) | 12 (29.3%)| 37 (31.9%)| 73 (43.7%)| 15 (68.2%)|
| Risk Diff (95% CI) | 10.24% (-8.17%,28.65%) | 5.97% (-9.28%,21.22%) | 3.35% (-7.17%,13.86%) | -8.47% (-18.23%,1.29%) | -32.94% (-53.37%,12.5%)
| P-value          | 1.000     | 0.058| 0.030     | 0.005     | 0.005     |
| Poor healing of perineal (N) | 227       | 24   | 41        | 116       | 167       | 22     |
| Yes(n, %)        | 227 (99.6%)| 24 (100.0%)| 41 (100.0%)| 116 (100.0%)| 167 (100.0%)| 22 (100.0%)
| No(n, %)         | 0 (0.4%)| 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%)|
| Risk Diff (95% CI) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%)
| P-value          | 1.000     | 1.000| 1.000     | 1.000     | 1.000     |
| Shoulder dystocia (N) | 227       | 24   | 41        | 116       | 167       | 22     |
| Yes(n, %)        | 227 (99.6%)| 24 (100.0%)| 41 (100.0%)| 116 (100.0%)| 167 (100.0%)| 22 (100.0%)
| No(n, %)         | 0 (0.4%)| 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%)|
| Risk Diff (95% CI) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%)
| P-value          | 1.000     | 1.000| 1.000     | 1.000     | 1.000     |
| Postoperative pyrexia (N) | 145       | 16   | 33        | 104       | 127       | 28     |
| Yes(n, %)        | 145 (97.9%)| 16 (100.0%)| 33 (100.0%)| 104 (100.0%)| 127 (100.0%)| 28 (100.0%)
| No(n, %)         | 3 (2.1%)| 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%)|
| Risk Diff (95% CI) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%) | 0.00% (-14.95%,16.9%)
| P-value          | 1.000     | 1.000| 1.000     | 1.000     | 1.000     |

PROM: Premature rupture of membrane; GDM: Gestational diabetes mellitus; CI: Confidence interval
with/without intervention or with/without contraction in each gestational group. In patients without spontaneous uterine contractions, iatrogenic intervention significantly decreased the rate of cesarean section at 38–38 + 6 and 39–39 + 6 weeks (p < 0.001 and 0.005, respectively), but there was no difference in the 40–40 + 6 and ≥ 41 gestational weeks groups. In patients with spontaneous uterine contractions, the cesarean section rate was decreased significantly at 40–40 + 6 weeks (p = 0.003) than in the 39–39 + 6 gestational weeks group, but there was no significant change with other delivery times.

Table 3  Neonatal Outcomes

| Gestational Week | 39–39 + 6 W | < 37 W | 37–37 + 6 W | 38–38 + 6 W | 40–40 + 6 W | ≥ 41 W |
|------------------|-------------|--------|-------------|-------------|-------------|--------|
| Weight N         | 372         | 40     | 74          | 220         | 372         | 293    |
| Mean ± SD (g)    | 2766 ± 348.86 | 3154 ± 444.46 | 3317 ± 430.14 | 3416 ± 424.87 | 3550 ± 379.32 | 3630 ± 440.42 |
| Median           | 2750        | 3100   | 3250        | 3400        | 3500        | 3575   |
| (Min, Max)       | (2200, 3950) | (2110, 4300) | (2350, 5200) | (2400, 4800) | (2500, 4700) | (2700, 4700) |
| Fetal macrosomia (N) | 369    | 40     | 74          | 219         | 294         | 50     |
| Yes(n, %)        | 38 (10.3%)  | 0      | 4 (5.4%)    | 15 (6.8%)   | 38 (12.9%)  | 10 (20.0%) |
| No(n, %)         | 331 (89.7%) | 40 (100.0%) | 70 (94.6%)  | 204 (93.2%) | 256 (87.1%) | 40 (80.0%) |
| Risk Diff (95% CI) | 10.30% (7.20%, 13.40%) | -4.89% (-10.91%, 1.12%) | -3.45% (-8.01%, 1.11%) | 2.63% (-3.20%, 7.56%) | 9.70% (-1.81%, 21.21%) |
| P-value          | 0.038       | 0.275   | 0.181       | 0.327       | 0.056       |
| III-polluted amniotic fluid (N) | 372       | 40     | 74          | 220         | 294         | 50     |
| Yes(n, %)        | 21 (5.6%)   | 0      | 0           | 5 (2.3%)    | 24 (8.2%)   | 4 (8.0%) |
| No(n, %)         | 351 (94.4%) | 100.0% | 100.0%      | 97.7%       | 91.8%       | 92.0%  |
| Risk Diff (95% CI) | 5.65% (3.30%, 7.99%) | 5.65% (3.30%, 7.99%) | -3.37% (-4.43%, -0.31%) | 2.52% (-1.39%, 6.43%) | 2.35% (-5.52%, 10.23%) |
| P-value          | 0.246       | 0.033   | 0.062       | 0.216       | 0.520       |
| Hypoglycemia (N) | 372         | 40     | 74          | 220         | 294         | 50     |
| Yes(n, %)        | 2 (0.5%)    | 1 (1.4%) | 5 (2.3%)    | 2 (0.7%)    | 1 (2.0%)    |
| No(n, %)         | 370 (99.5%) | 98.6%  | 98.6%       | 97.7%       | 99.3%       | 98.0%  |
| Risk Diff (95% CI) | 4.46% (2.33%, 11.26%) | 0.81% (-1.92%, 3.55%) | 1.74% (-0.37%, 3.84%) | 0.14% (-1.06%, 1.34%) | 1.46% (-2.49%, 5.41%) |
| P-value          | 0.049       | 0.421   | 0.108       | 1.000       | 0.316       |
| Spitting and groaning (N) | 372       | 40     | 74          | 220         | 294         | 50     |
| Yes(n, %)        | 14 (3.8%)   | 5 (12.5%) | 2 (2.7%)    | 3 (1.4%)    | 10 (3.4%)   |
| No(n, %)         | 358 (96.2%) | 87.5%  | 97.3%       | 98.6%       | 96.6%       | 100.0% |
| Risk Diff (95% CI) | 8.74% (1.69%, 19.17%) | -1.06% (-5.23%, 3.11%) | -2.40% (-4.87%, 0.07%) | -0.36% (-3.20%, 2.47%) | 3.76% (1.83%, 5.70%) |
| P-value          | 0.028       | 1.000   | 0.126       | 0.838       | 0.390       |
| Asphyxia Neonatorum (N) | 372       | 40     | 74          | 220         | 294         | 50     |
| Yes(n, %)        | 3 (0.8%)    | 1 (1.4%) | 2 (0.9%)    | 4 (1.4%)    | 1 (2.0%)    |
| No(n, %)         | 369 (99.2%) | 98.6%  | 98.6%       | 99.1%       | 98.0%       | 98.0%  |
| Risk Diff (95% CI) | 0.81% (-0.10%, 1.72%) | 0.54% (-2.24%, 3.33%) | 0.10% (-1.45%, 1.65%) | 0.55% (-1.05%, 2.16%) | 1.19% (-2.79%, 5.18%) |
| P-value          | 1.000       | 0.517   | 1.000       | 0.705       | 0.397       |
| Neonatal Respiratory Distress (N) | 372       | 40     | 74          | 220         | 294         | 50     |
| Yes(n, %)        | 0           | 0      | 0           | 0           | 1 (0.3%)    |
| No(n, %)         | 372 (100.0%) | 100.0% | 100.0%      | 100.0%      | 99.7%       | 50 (100.0%) |
| Risk Diff (95% CI) | 0           | 0      | 0           | 0           | 0           | 0      |
| P-value          | 1.000       | 1.000   | 1.000       | 1.000       | 1.000       |
| Neonatal Malformation (N) | 372       | 40     | 74          | 220         | 294         | 50     |
| Yes(n, %)        | 3 (0.8%)    | 0      | 0           | 0           | 2 (0.7%)    |
| No(n, %)         | 369 (99.2%) | 100.0% | 100.0%      | 100.0%      | 99.3%       | 100.0% |
| Risk Diff (95% CI) | 0.81% (-0.10%, 1.72%) | 0.81% (-0.10%, 1.72%) | -0.13% (-1.43%, 1.18%) | 0.81% (-0.10%, 1.72%) |
| P-value          | 1.000       | 1.000   | 0.298       | 1.000       | 1.000       |

SD: Standard deviation; CI: Confidence interval
| Gestational Week | 39–39⁺6 W | <37 W | 37–37⁺6 W | 38–38⁺6 W | 40–40⁺6 W | ⩾41 W |
|------------------|-----------|------|-----------|-----------|-----------|------|
| **Indications for Cesarean Section** | | | | | | |
| Macrosomia (N) | | | | | | |
| Yes(n, %) | 19 (41.3%) | 0 | 3 (16.7%) | 8 (18.2%) | 19 (52.8%) | 2 (28.6%) |
| No(n, %) | 27 (58.7%) | 8 (100.0%) | 15 (83.3%) | 36 (81.8%) | 17 (47.2%) | 5 (71.4%) |
| Risk Diff (95% CI) | 41.30% (27.08%,55.53%) | -246.4% (-469.97%, -2.30%) | -23.12% (-413.55%, -4.89%) | 11.47% (-1017.3312%, -127%) | -127% (-910.2363%, -2.73%) |
| P-value | 0.040 | 0.082 | 0.374 | 0.690 | |
| Fetal distress (N) | | | | | | |
| Yes(n, %) | 46 (19.6%) | 8 (100.0%) | 44 (81.8%) | 36 (81.8%) | 7 (100.0%) |
| No(n, %) | 27 (58.7%) | 0 (0.0%) | 15 (83.3%) | 36 (81.8%) | 0 (0.0%) |
| Risk Diff (95% CI) | 5.43% (-26.69%,37.5%) | -14.01% (-29.61%,1.59%) | -8.20% (-23.01%,3.14%) | -19.62% (-25.13%,12.68%) |
| P-value | 0.040 | 0.082 | 0.374 | 0.690 | |
| GDM (N) | | | | | | |
| Yes(n, %) | 7 (15.2%) | 1 (12.5%) | 3 (16.7%) | 13 (29.5%) | 2 (5.6%) |
| No(n, %) | 39 (84.8%) | 7 (87.5%) | 15 (83.3%) | 31 (70.5%) | 34 (94.4%) |
| Risk Diff (95% CI) | -2.72% (-27.88%,22.4%) | 1.45% (-18.65%,21.5%) | 14.33% (-26.99%,31.34%) | 19.57% (-28.86%,26.9%) |
| P-value | 0.040 | 0.082 | 0.374 | 0.690 | |
| Oligohydramnios (N) | | | | | | |
| Yes(n, %) | 46 (9.6%) | 8 (100.0%) | 44 (81.8%) | 36 (81.8%) | 7 (100.0%) |
| No(n, %) | 27 (58.7%) | 0 (0.0%) | 15 (83.3%) | 36 (81.8%) | 0 (0.0%) |
| Risk Diff (95% CI) | 6.52% (-0.61%,13.66%) | 21.26% (-0.63%,43.14%) | 18.48% (3.83%,33.13%) | 17.05% (0.36%,31.04%) |
| P-value | 0.040 | 0.082 | 0.374 | 0.690 | |
| Preeclampsia (N) | | | | | | |
| Yes(n, %) | 8 (17.4%) | 5 (62.5%) | 6 (33.3%) | 7 (15.9%) | 3 (8.3%) |
| No(n, %) | 38 (82.6%) | 3 (37.5%) | 12 (66.7%) | 33 (75.0%) | 33 (91.7%) |
| Risk Diff (95% CI) | 45.11% (9.82%,80.40%) | 15.94% (-8.43%,40.32%) | -1.48% (-16.87%,13.9%) | -9.06% (-23.25%,15.4%) |
| P-value | 0.040 | 0.082 | 0.374 | 0.690 | |
| Trial of labor | | | | | | |
| Vaginal Delivery (n, %) | 227 (88.7%) | 24 (96.0%) | 41 (93.2%) | 116 (95.1%) | 167 (82.3%) |
| Natural Labor switched to C-section (n, %) | 29 (11.3%) | 1 (4.0%) | 3 (6.8%) | 6 (4.9%) | 36 (17.7%) |
| Risk Diff (95% CI) | -7.33% (-15.93%,1.28%) | -4.51% (-19.12%,4.89%) | -6.41% (-14.82%,1.95%) | 6.41% (-11.87%,12.94%) |
| P-value | 0.040 | 0.082 | 0.374 | 0.690 | |
| Natural Labor Rate | | | | | | |
| Iatrogenic Intervention (N) | | | | | | |
| Yes(n, %) | 46 (9.6%) | 8 (100.0%) | 44 (81.8%) | 36 (81.8%) | 7 (100.0%) |
| No(n, %) | 27 (58.7%) | 0 (0.0%) | 15 (83.3%) | 36 (81.8%) | 0 (0.0%) |
| Risk Diff (95% CI) | 6.52% (-0.61%,13.66%) | 21.26% (-0.63%,43.14%) | 18.48% (3.83%,33.13%) | 17.05% (0.36%,31.04%) |
| P-value | 0.040 | 0.082 | 0.374 | 0.690 | |

Legend: NL, Natural Labor; WI, With Intervention; WOI, Without Intervention; WC, With contraction; WOC, Without contraction; CI: Confidence interval
Discussion
The present study analyzed data in patients with diet-controlled GDM. The rate of cesarean section was increased significantly at ≥41 gestational weeks, but it showed no difference between the 39–39 + 6 and 40–40 + 6 gestational weeks groups. The rate of natural labor switching to cesarean section was slightly increased in the 40–40 + 6 and ≥41 gestational weeks groups compared to that in the 39–39 + 6 group; the difference was not significant (p = 0.059 and 0.071 respectively). For the patients without spontaneous uterine contractions, the rate of vaginal delivery with iatrogenic intervention was increased significantly at 39–39 + 6 weeks (p = 0.005), but it did not increase at 40–40 + 6 and 41 weeks (p = 0.480 and 0.773 respectively). Finally, in the patients with spontaneous uterine contractions, the rate of vaginal delivery was increased significantly at 40–40 + 6 weeks (p = 0.003), and slightly increased at 39–39 + 6 weeks (p = 0.072), but the difference was not significant.

Deciding on the optimal timing of delivery requires balancing the conflict between maternal and fetal benefits and the risk of complications [20]. Joep et al. [21] found that the rate of adverse maternal–fetal risks was increased significantly after 41 gestational weeks for singleton pregnancies without complications such as hypertension or diabetes. Our study found that the cesarean section rate was significantly increased at 41 gestational weeks compared to that at 39–39 + 6 weeks. The rate of multiple adverse outcomes (macrosomia, III-polluted amniotic fluid, neonatal hypoglycemia) was slightly increased at 41 weeks compared to 39–39 + 6 weeks, although the difference was not statistically significant. Therefore, patients with diet-controlled GDM should not deliver after 41 weeks of gestation, which is also recommended for other singleton pregnancies.

As mentioned earlier, the recommended time of delivery for patients with medication-treated GDM is 39–39 + 6 weeks of gestation. This raises the question of whether delivery should also be indicated before 39 gestational weeks for diet-controlled GDM. In 2013, ACOG, gynecologists, and the Society for Maternal–Fetal Medicine [22] stated that they had long discouraged non-indicated delivery before 39 weeks of gestation, and diet-controlled GDM was not an indication. Several studies [11, 23, 24] found that the rate of access to neonatal intensive care units, hypoglycemia, weight loss, and cesarean delivery due to induction of labor were increased when delivery occurred before 39 weeks of gestation for diet-controlled GDM. In our study, however, there were no significant increases in adverse maternal and neonatal outcomes before 39 weeks of gestation when compared to those after 39 weeks, even the natural labor switching to cesarean section rate was slightly decreased in the 38–38 + 6 gestational weeks (p = 0.056). But with the absence of risks after 39 weeks of GDM, we do not recommend iatrogenic intervention before 39 weeks of gestation to avoid an early-term birth.

According to the analysis, the optimal delivery time for patients with diet-controlled GDM should be between 39–40 + 6 weeks of gestation. We analyzed the data of patients who underwent delivery during this period separately according to whether they had spontaneous uterine contractions. In patients without contractions, we found that the rate of vaginal delivery was increased significantly at 39–39 + 6 gestational weeks when given iatrogenic intervention, but there were no differences in the vaginal delivery rate at 40–40 + 6 gestational weeks. This is the same with a study involving Chinese pregnant women on induction of labor with dinoprostone in a patient with GDM [25]. Therefore, we recommend that iatrogenic intervention be performed at 39–39 + 6 weeks of gestation to induce labor. In patients with spontaneous uterine contractions starting at 40–40 + 6 weeks of gestation, the rate of vaginal delivery was significantly higher than that of cesarean section delivery. Otherwise, the rate of cesarean delivery was increased significantly at 40–40 + 6 weeks of gestation in the absence of spontaneous uterine contractions.

Conclusions
Generally, we recommend the optimal delivery time for patients with diet-controlled GDM to be between 39 and 40 + 6 weeks of gestation. The Bishop score of patients should be assessed at 39–39 + 6 weeks of gestation, and for those with a Bishop score below 4, iatrogenic intervention is not recommended. Waiting for spontaneous uterine contractions under close management may be a better choice.

This study had some limitations. Although the data was collected from one of the largest hospitals in the region, this was only a single-center study. Patients at higher-rated hospitals usually receive better management than those at lower-rated hospitals, which may have led to bias in maternal and neonatal outcomes. Prospective and multicenter cohort studies may reduce bias and provide more convincing conclusions in the future.

Abbreviations
GDM: Gestational diabetes mellitus; PROM: Premature rupture of membrane; ACOG: American College of Obstetricians and Gynecologists; SOGC: Society of Obstetricians and Gynecologists of Canada; OGTT: 75-Gram oral glucose tolerance test; FPG: Fasting plasma glucose; PPH: Postpartum hemorrhage.

Acknowledgements
We thank Professor Wai-Kit Ming from the Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China, who helped to review this paper.
Authors’ contributions
Y.Z. and L.T. wrote the manuscript and collected data. Z.L. collected data and contributed to the discussion. F.J., S.J., L.D. collected data and reviewed/edited the manuscript. Zangzhi Yin, Tengteng Li, and Lu Zhou made equal contributions to this paper. All authors have approved the final article.

Funding
This work was supported by the National Natural Science Foundation of China (No. 82071679), Natural Science Foundation of Anhui Province (No. 2008085MH286), and Basic and Clinical Cooperative Research Promotion Program of Anhui Medical University (No. 2019kjt020) for the analysis and interpretation of data and in the writing of the report.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to the private information of the patients but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study design was approved by the First Affiliated Hospital of Anhui Medical University Ethics Committee for the Protection of Human Subjects in Research. The need for acquisition of informed consent was waived by First Affiliated Hospital of Anhui Medical University Ethics Committee for the Protection of Human Subjects in Research owing to the retrospective nature of this study.

Consent for publication
N/A

Competing interests
The authors declare that they have no conflict of interest.

Author details
1 Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. 2 Department of Obstetrics and Gynecology, Chaohu Hospital of Anhui Medical University, Chaohu 238001, China. 3 NHIC Key Laboratory of the Study of Abnormal Gametes and the Reproductive Tract, Anhui Medical University, Hefei 230022, China. 4 Department of Scientific Research, The Second Affiliated Hospital of Anhui Medical University, Hefei 230021, China.

References
1. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, Cabero Roua L, McIntyre HD, Morris JL, Divakar H (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynecol Obstet. 2015;131:517-21. https://doi.org/10.1002/ijgo.200333.3.
2. ACOG Practice Bulletin No. 190 (2018) ACOG Practice Bulletin No. 190: Gestational diabetes mellitus; Obstet Gynecol. 2013;111:1498-4. doi: https://doi.org/10.1097/AOG.0000000000002501
3. McIntyre HD, Catalano P, Zhang C, Desouy G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019;5:47. https://doi.org/10.1038/s41572-019-0098-8.
4. Oskivi-Kaplan ZA, Ozgu-Erdinc AS. Management of gestational Diabetes Mellitus. Adv Exp Med Biol. 2021;190:257–72. https://doi.org/10.1007/5884_2020_552.
5. Zhang X, Liao Q, Wang F, LiD. Association of gestational diabetes and abnormal vaginal flora with adverse pregnancy outcomes. Medicine (Baltimore). 2018;97:e11891. https://doi.org/10.1097/MD.0000000000011891.
6. El-Mallah KO, Narchi H, Kulyatif NA, Shaban MS. Gestational and pre-gestational diabetes: Comparison of maternal and fetal characteristics and outcome. Int J Gynaecol Obstet. 1997;58:203–9. https://doi.org/10.1016/S0020-7292(97)00084-2.
7. Zhuang W, Li J, Liang Q, Chen W, Zhang S, Sun X. Adverse effects of gestational diabetes-related risk factors on pregnancy outcomes and intervention measures. Exp Ther Med. 2020;20:3361–7. https://doi.org/10.3892/etm.2020.9050.
8. Barrett HL, Morris J, McElduff A. Watchful waiting: A management protocol for maternal glycaemia in the peripartum period. Aust N Z Obstet Gynaecol. 2009;49:162–7. https://doi.org/10.1111/j.1479-828X.2009.00969.x.
9. Ehrenberg HM, Durward CP, Catalano P, Mercer BM. The influence of obesity and diabetes on the risk of cesarean delivery. Am J Obstet Gynecol. 2004;191:969–74. https://doi.org/10.1016/j.ajog.2004.06.057.
10. Berger H, Gagnon R, Sermer M. Guideline No. 393 (2019) Guideline No. 393-Diabetes in pregnancy. J Obstet Gynaecol Can 41:1814–1825.e1. doi: https://doi.org/10.1016/j.jogc.2019.03.008.
11. Niu B, Lee VR, Cheng YW, Fries AE, Nicholson JM, Caughey AB. What is the optimal gestational age for women with gestational diabetes type A1 to deliver? Am J Obstet Gynecol 2014;211:4181-4186. https://doi.org/10.1016/j.ajog.2014.06.015.
12. Alberico S, Erenbourg A, Hod M, Yogev Y, Hadar E, Neri F, Ronfani L, Maso G, GINEXMAL Group. Immediate delivery or expectant management in gestational diabetes at term: The GINEXMAL randomised controlled trial. BJOG. 2017;124:669–77. https://doi.org/10.1111/1471-0528.14389.
13. Karmon A, Levy A, Holcberg G, Wiznitzer A, Mazor M, Sheiner E. Decreased perinatal mortality among women with diet-controlled gestational diabetes mellitus. Int J Gynaecol Obstet. 2009;104:199–202. https://doi.org/10.1016/j.ijgo.2008.09.016.
14. Obstetrics subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Diabetes in pregnancy: Diagnosis and treatment (2014). Chin J Obstet Gynecol, (Published in Chinese). 2014;49:80. 61–69.
15. Obstetrics subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Diagnosis and management of hypertension in pregnancy (2020). Chin J Obstet Gynecol (Published in Chinese). 2020;55(4): 227–28.
16. Obstetrics subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Diagnosis and management of premature rupture of membranes (2015). Chin J Obstet Gynecol (Published in Chinese). 2015;50(1): 3–8.
17. Obstetrics subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Prevention and treatment of postpartum hemorrhage (2014). Chin J Obstet Gynecol (Published in Chinese). 2014;49(9): 641–6.
18. Neonatal Resuscitation subgroup, Chinese Society of Perinatal Medicine, Chinese Medical Association. Expert consensus on the diagnosis of neonatal asphyxia (2016). Chin J Perinat Med (Published in Chinese). 2016;19(1):3–6.
19. Jing Li. Diagnosis and treatment of neonatal respiratory distress (2013). Chin J Appl Clin Pediatr (Published in Chinese). 2013;28(14):1117–20.
20. Spong CY, Mercer BM, D'Alton M, Kilpatrick S, Blackwell S, Saade G. Timing of indicated late-preterm and early-term birth. Obstet Gynecol. 2011;118:323–33. https://doi.org/10.1097/AOG.0b013e328225599.
21. Kortekaas JC, Kazemier BM, Keulen JK, Bruinisma A, Mol BW, Van den Bussche F, Van Dillen J, De Miranda E. Risk of adverse pregnancy outcomes of late- and postterm pregnancies in advanced maternal age: A national cohort study. Acta Obstet Gynecol Scand. 2020;99:1022–30. https://doi.org/10.1111/aogs.13828.
22. ACOG committee opinion no. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol. 2013;121:908–10. https://doi.org/10.1097/AOG.0b013e328a755480.
23. Rosenstein MG, Cheng YW, Snowden JM, Nicholson JM, Doss AE, Caughey AB. The risk of stillbirth and infant death stratified by gestational age in women with gestational diabetes. Am J Obstet Gynecol. 2012;206:598.e1–7. https://doi.org/10.1016/j.ajog.2012.01.014.
24. Melamed N, Ray JG, Geary M, Bedard D, Yang C, Sprague A, Murray-Davis B, Barrett J, Berger H. (2016) Induction of labor before 40 weeks is associated with lower rate of cesarean delivery in women with gestational diabetes mellitus. Am J Obstet Gynecol 214:364.e1–364.e8.e3648. doi: https://doi.org/10.1016/j.ajog.2015.12.021.
25. Jiang T-T, Zhao L, Lin Y, Zhou D, Wang L, Sun G-Q, Xiao M. Effects of gestational diabetes mellitus on time to delivery and pregnancy outcomes in full-term pregnancies with dinoprostone labor induction. Clin Exp Hypertens. 2019;41(1):44–8. https://doi.org/10.1080/10641963.2018.144185.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.